Diabetes in Special Populations

  • Ronald A. Codario
Chapter
Part of the Current Clinical Practice book series (CCP)

Abstract

Major depressive disorders and depressive symptoms not only occur frequently with diabetes, but in many patients, mental health symptoms and even depression go unrecognized or incorrectly diagnosed [1]. Even among those that undergo successful treatment, close to 80% will experience relapsing symptoms within 5 years. Diabetic patients at higher risk for depression include those of female gender, poor social support system, lower education, low socioeconomic status, and unmarried status. Clinical research has revealed that having type-2 diabetes increases the risk of depression and depression is an independent risk and predictive factor for the quantity and severity of type-2 diabetes complications. Depression early in life also increases the risk for unhealthy lifestyle, obesity, sedentary existence, and addictive habits – especially smoking. In addition, patients with depression and type-2 diabetes are far more likely to be non-compliant with medications, glucose self monitoring, and therapeutic life style changes [1].

Key Words

Mental health Type-2 diabetes in children Diabetes in women Acquired immune deficiency syndrome (AIDS) Hemodialysis Foot problems Perioperative and postoperative glycemic control Skin disease in type-2 diabetic patients 

References

  1. 1.
    Knol MJ, Twisk JW, Beekman AT, Heine RJ, Snoek FJ, Pouwer F. Depression as a risk factor for type-2 diabetes mellitis. Diabetologia. 2006;49:837–845.CrossRefPubMedGoogle Scholar
  2. 2.
    Jindal RD, Keshavan MS. Critical role of M3 muscarinic receptor in insulin secretion. J Clin Psychopharmacol. 2006;26(5):449–450.CrossRefPubMedGoogle Scholar
  3. 3.
    Gilon P, Henquin JC. Mechanisms and physiological significance of the cholinergic control to pancreatic beta cell function. Endocr Rev. 2001;22(5):565–604.CrossRefPubMedGoogle Scholar
  4. 4.
    Gautam D, Han SJ, Hamdan FF. A critical role for beta cell M3 muscarinic acetylcholine receptors in regulating insulin release and blood glucose homeostasis in vivo. Cell Metab. 2006;3(6):449–461.CrossRefPubMedGoogle Scholar
  5. 5.
    Renuka TR, Robinson R, Paulose GS. Increased insulin secretion by muscarinic M1 and M3 receptor function from rat pancreatic islets in vivo. Neurochem Res. 2006;31(3):313–320.CrossRefPubMedGoogle Scholar
  6. 6.
    American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs, obesity and diabetes. Diabetes Care. 2004;27(2):595–601.Google Scholar
  7. 7.
    Fava M. Weight gain and antidepressants. J Clin Psychiatry. 2000;61(suppl 11):37–41.PubMedGoogle Scholar
  8. 8.
    Ackerman S, Nolan LJ. Bodyweight gain induced by psychotropic drugs. Incidence, mechanisms, and management. CNS Drugs. 1998;9:135–151.CrossRefGoogle Scholar
  9. 9.
    Fagot-Campagna A, Pettitt DJ, Englegau MM, Burrows NR, Geiss LS, Valdez R. Type-2 diabetes among North American children and adolescents. J Pediatr. 2000;136:664–672.CrossRefPubMedGoogle Scholar
  10. 10.
    Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States 1999-2004. JAMA. 2006;295(13):1549–1555.CrossRefPubMedGoogle Scholar
  11. 11.
    Molnar D. The prevalence of the metabolic syndrome and type-2 diabetes mellitus in children and adolescents. Int J Obes Relat Metab Disord. 2004;28(suppl 3):570–574.Google Scholar
  12. 12.
    Legro RE, Kunselman AR, Dodson WC. Prevalence and predictors of risk for type-2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome. J Clin Endocrinol Metab. 1999;84:165–169.CrossRefPubMedGoogle Scholar
  13. 13.
    Weiss R, Dziura J, Burgert TS. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med. 2004;350:2362–2374.CrossRefPubMedGoogle Scholar
  14. 14.
    American Diabetes Association. Type-2 diabetes in children and adolescents: consensus statement. Diabetes Care. 2000;23:381–389.CrossRefGoogle Scholar
  15. 15.
    Vinicor F. Diabetes and Women’s Health Across the Life Stages: A Public Health Perspective. Atlanta: Centers for Disease Control, US Department of Health and Human Services; 2002.Google Scholar
  16. 16.
    Narayan KM, Boyle JP, Thompson TJ, Sorenson SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA. 2003;290(14):1884–1890.CrossRefPubMedGoogle Scholar
  17. 17.
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.CrossRefGoogle Scholar
  18. 18.
    Knowler WC, Barrett-Connor E, Fowler SE. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403.CrossRefPubMedGoogle Scholar
  19. 19.
    Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356–359.CrossRefPubMedGoogle Scholar
  20. 20.
    Isomaa B, Almgren P, Tuomi T. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:2486–2497.CrossRefGoogle Scholar
  21. 21.
    Jack L, Boseman L, Vinicor F. Aging Americans and diabetes. A public health and clinical response. Geriatrics. 2004;59:14–17.PubMedGoogle Scholar
  22. 22.
    Smedley BD, Stith AY, Nelson AR. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Washington, DC: National Academic Press; 2003.Google Scholar
  23. 23.
    Harris MI, Flegal KM, Cowie CC. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey. Diabetes Care. 1998;21:136–144.Google Scholar
  24. 24.
    American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2004;27(suppl 1):S15–S35.Google Scholar
  25. 25.
    Tuomilehto J, Lindstrom J,Eriksson JG. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–1350.CrossRefPubMedGoogle Scholar
  26. 26.
    Kanaya AM, Narayan KM. Prevention of type 2 diabetes: data from recent trials. Prim Care. 2003;30:511–526.CrossRefPubMedGoogle Scholar
  27. 27.
    Buchanan TA, Xiang AH, Peters RK. Prevention of type 2 diabetes by treatment of insulin resistance: comparison of early vs. late intervention in the TRIPOD study. Diabetes. 2002;51(suppl 2):A35.Google Scholar
  28. 28.
    Moses RG. The recurrence rate of gestational diabetes in subsequent pregnancies. Diabetes Care. 1996;19(12):1348–1350.CrossRefPubMedGoogle Scholar
  29. 29.
    Dornhorst A, Rossi M. Risk and prevention of type 2 diabetes in women with gestational diabetes. Diabetes Care. 1998;21(suppl 2):B43–B49.PubMedGoogle Scholar
  30. 30.
    Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2000;23(suppl 1):S4–S19.Google Scholar
  31. 31.
    Jovanovic L, Pettit DJ. Gestational diabetes mellitus. JAMA. 2001;286:2516–2518.CrossRefPubMedGoogle Scholar
  32. 32.
    Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care. 2002;25:1862–1868.CrossRefPubMedGoogle Scholar
  33. 33.
    Pietropaolo M, LeRoith D. Pathogenesis of diabetes: our current understanding. Clin Cornerstone. 2001;4:1–16.CrossRefPubMedGoogle Scholar
  34. 34.
    Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA. 1999;281:1291–1297.CrossRefPubMedGoogle Scholar
  35. 35.
    Downs JR, Clearfield M, Weis S. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA. 1998;279:1615–1622.CrossRefPubMedGoogle Scholar
  36. 36.
    Assmann G, Carmena R, Cullen P. Coronary heart disease: reducing the risk: a worldwide view. International Task Force for the Prevention of Coronary Disease. Circulation. 1999;100:1930–1938.CrossRefPubMedGoogle Scholar
  37. 37.
    Wilson PW. Diabetes mellitus and coronary heart disease. Am J Kidney Dis. 1998:32:S89–S100.CrossRefPubMedGoogle Scholar
  38. 38.
    Gaede P, Vedel P, Larsen N. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–393.CrossRefPubMedGoogle Scholar
  39. 39.
    UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and mcirovascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703–713.CrossRefGoogle Scholar
  40. 40.
    Vega Gl. Results of expert meetings: obesity and cardiovascular disease. Obesity, the metabolic syndrome and cardivascular disease. Am Heart J. 2001;142:1108–1116.CrossRefPubMedGoogle Scholar
  41. 41.
    Deen D. Metabolic syndrome: time for action. Am Fam Physicain. 2004;69:2875–2882.PubMedGoogle Scholar
  42. 42.
    Wilson PW, Grundy SM. The metabolic syndrome: practical guide to origins and treatment. Circulation. 2003;108:1422–1424.CrossRefPubMedGoogle Scholar
  43. 43.
    Knowler WC, Barnett-Conner E, Fowler SE, Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.CrossRefPubMedGoogle Scholar
  44. 44.
    Zinman B, Ruderman N, Campaigne BN, Devlin JT, Schneider SH, American Diabetes Association. Physical activity exercise and diabetes mellitus. Diabetes Care. 2003;26(suppl 1):S73–S77.PubMedGoogle Scholar
  45. 45.
    Rossouw JE, Anerson GL, Prentice RL. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–333.CrossRefPubMedGoogle Scholar
  46. 46.
    Hulley S, Grady D, Bush T. Randomized controlled trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605–613.CrossRefPubMedGoogle Scholar
  47. 47.
    Manning P, Allum A, Jones S, Sutherland W, Williams S. The effect of hormone replacement therapy on cardiovascular risk factors in type 2 diabetes. Arch Intern Med. 2001;161:1772–1776.CrossRefPubMedGoogle Scholar
  48. 48.
    Herrington DM, Vittinghoff E, Lin F. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation. 2002;105:2962–2967.CrossRefPubMedGoogle Scholar
  49. 49.
    Malmberg K. Prospective randomized study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI) Study Group. BMJ. 1997;314:1512–1514.CrossRefPubMedGoogle Scholar
  50. 50.
    Kjekshus J, Gilpin E, Cali G, Blackey AR, Henning H, Ross J. Diabetic patients and beta-blockers after acute myocardial infarction. Eur Heart J. 1990;11:43–50.PubMedGoogle Scholar
  51. 51.
    Chen J. Beta blockers in elderly diabetic patients post myocardial infarction. J Am Coll Cardiol. 1999;34:1388–1394.CrossRefPubMedGoogle Scholar
  52. 52.
    Bakris G, Bell D, Fonseca V. GEMINI Investigators. The rationale and design of the glycemic effects in diabetes mellitus. JAMA. 2004;292(18):2227–2236.Google Scholar
  53. 53.
    Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE. Exercise mortality among men referred for exercise testing. N Engl J Med. 2001;346:793–801.CrossRefGoogle Scholar
  54. 54.
    Vinik A, Flemmer M. Diabetes and macrovascular disease. J Diabetes Complications. 2002;16:235–245.CrossRefPubMedGoogle Scholar
  55. 55.
    Patterson JE, Andriole VT. Bacterial urinary tract infections in diabetes. Infect Dis Clin North Am. 1995;9:25–51.PubMedGoogle Scholar
  56. 56.
    Patterson JE, Andriole V. Bacterial urinary tract infections in diabetes. Infect Dis Clin North Am. 1997;11(3):735–750.CrossRefPubMedGoogle Scholar
  57. 57.
    Lunt H. Women and diabetes. Diabet Med. 1996;13(12):1009–1016.CrossRefPubMedGoogle Scholar
  58. 58.
    Rayfield EJ, Ault MJ, Keusch GT. Infection and diabetes: the case for glucose control. Am J Med. 1982;72(3):439–450.CrossRefPubMedGoogle Scholar
  59. 59.
    Addison WA, Livingood CH, Hill GB. Recurrent necrotizing fasciitis of vulvar origin in diabetic patients. Obstet Gynecol.1984;63(4):473–479.PubMedGoogle Scholar
  60. 60.
    Bohannon NJ. Treatment of vulvovaginal candidiasis in patients with diabetes. Diabetes Care. 1998;21(3):451–456.CrossRefPubMedGoogle Scholar
  61. 61.
    Bell DS, Clements RS, Cutter GR, Whitey RJ. Condylomata acuminata in IDDM. Diabetes Care. 1988;11(3):295–296.PubMedGoogle Scholar
  62. 62.
    Stenchever MA, Herbst AL, Mishell DR (eds). Comprehensive Gynecology, 4th ed. St. Louis: Mosby; 2001.Google Scholar
  63. 63.
    Peer AK, Hoosen AA, Seedat MA. Vaginal yeast infections in diabetic women. S Afr Med J. 1993;83(10):727–729.PubMedGoogle Scholar
  64. 64.
    Tobin MJ. Vulvovaginal candidiasis: topical versus oral therapy. Am Fam Physician. 1995:51:1715–1720.PubMedGoogle Scholar
  65. 65.
    Coats AJ. Angiotensin receptor blockers – finally the evidence is coming in: IDNT and RENAAL. Int J Cardiol. 2001;79:99–102.CrossRefPubMedGoogle Scholar
  66. 66.
    Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253–259.CrossRefGoogle Scholar
  67. 67.
    Spanheimer RG. Reducing cardiovascular risk in diabetes. Which factors to modify first? Postgrad Med. 2001;109:26–30; 33–36.Google Scholar
  68. 68.
    Adler AI, Stratton IM, Neil HA. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412–419.CrossRefPubMedGoogle Scholar
  69. 69.
    Colwell JA, American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care. 2003;26(suppl 1):S87–S88.PubMedGoogle Scholar
  70. 70.
    Hansson L, Zanchetti A, Carruthers SG. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) Randomized Trial (HOT Study Group). Lancet. 1998;351:1755–1762.CrossRefPubMedGoogle Scholar
  71. 71.
    CAPRIE Steering Committee. Randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 1996;348:1329–1339.CrossRefGoogle Scholar
  72. 72.
    Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–393.CrossRefPubMedGoogle Scholar
  73. 73.
    American Diabetes Association. Gestational diabetes mellitus. Diabetes Care. 2004;27(suppl 1):S88–S90.Google Scholar
  74. 74.
    Clapp IF. Exercise during pregnancy: a clinical update. Clin Sports Med. 2000;19:273–286.CrossRefPubMedGoogle Scholar
  75. 75.
    Bertinin AM, Silva JC, Taborda W. Perinatal outcomes and the use of oral hypoglycemic agents. J Perinat Med. 2005;33(6):519–523.Google Scholar
  76. 76.
    Jacobson GF, Ramos GA, Ching JY, Kirby RS, Ferrara A, Field DR. Comparison of glycburide and insulin for the management of gestational diabetes in a large managed care population. Am J Obstet Gynecol. 2005;193(1):118–124.CrossRefPubMedGoogle Scholar
  77. 77.
    Brody SC, Harris R, Lohr K. Screening for gestational diabetes: a summary of evidence for the U.S. Preventive Services task Force. Obstet Gynecol. 2003;101(2):380–392.CrossRefPubMedGoogle Scholar
  78. 78.
    Kim C, Herman WH, Vijan S. Efficacy and cost of postpartum screening strategies for diabetes among women with histories of gestational diabetes mellitus. Diabets Care. 2007;30(5):1102–1106.CrossRefGoogle Scholar
  79. 79.
    Rowan J, Hague W, Wanzhen G, Battin M, Moore P. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med. 2008;358:2003–2015.CrossRefPubMedGoogle Scholar
  80. 80.
    Langer O, Brustman L, Anyaegbunam A, Mazze R. The significance of one abnormal glucose tolerance test value on adverse outcome in pregnancy. Am J Obstet Gynecol. 1987;157:758–763.PubMedGoogle Scholar
  81. 81.
    Landon MB, Vickers S. Fetal surveillance in pregnancy complicated by diabetes mellitus: is it necessary? J Matern Fetal Neonatal Med. 2002;12:413–416.CrossRefPubMedGoogle Scholar
  82. 82.
    Meneilly GS, Tessier D. Diabetes in elderly adults. J Gerontol A Biol Sci Med Sci. 2001;56:M5–M13.CrossRefPubMedGoogle Scholar
  83. 83.
    Franse LV, di Bari M, Shorr RI, Health, Aging, and Body Composition Study. Type 2 diabetes in older well functioning people. Data from the Health, Aging, and Body composition study. Diabetes Care. 2001;24:2065–2070. Diabetes Care. 2002;25:413.Google Scholar
  84. 84.
    Katakura M, Naka M, Kondo T, and the Nagano Elderly Diabetes Study Group. Normal mortality in the elderly with diabetes under strict glycemic and blood pressure control. Diabetes Res Clin Pract. 2007;78:108–114.Google Scholar
  85. 85.
    Johnston PS, Lebovitz HE, Coniff RF, Simonson DC, Raskin P, Munera CL. Advantages of alpha glucosidase inhibition as monotherapy in elderly type-2 diabetic patients. J Clin Endocrinol Metab. 1998;83(5):1515–1522.CrossRefPubMedGoogle Scholar
  86. 86.
    Jain MK, Aragaki C, Fischbach L. Hepatitis C is associated with type 2 diabetes mellitus in HIV infected persons without traditional risk factors. HIV Med. 2007;8:491–497.CrossRefPubMedGoogle Scholar
  87. 87.
    Brown TT, Cole SR, Li X. Antiretroviral therapy and the prevalence and incidence of diabetes. Arch Intern Med. 2005;165:2537.CrossRefGoogle Scholar
  88. 88.
    Tebas P.Insulin resistance and diabetes mellitus associated with antiretroviral use in HIV infected patients. J Acquir Immune defic Syndr. 2008;49(suppl 2):S86–S92.CrossRefPubMedGoogle Scholar
  89. 89.
    Saint-Marc T, Touraine JL. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy. AIDS. 1999;13:1000–1002.CrossRefPubMedGoogle Scholar
  90. 90.
    National Institute of Diabetes and Digestive and Kidney Diseases. United States Renal Data System: USRDS 2005 Annual Data Report. Bethesda, MD: National Institutes of Health; 2005.Google Scholar
  91. 91.
    Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial. 2004;17:365–370.CrossRefPubMedGoogle Scholar
  92. 92.
    Ahmed I, Goldstein B. Diabetes mellitus. Clin Dermatol. 2006;24:237–246.CrossRefPubMedGoogle Scholar
  93. 93.
    Dittmar M, Kahaly GJ. Polyglandular autoimmune syndromes:immunogenetics and long term follow up. J Clin Endocrinol Metab. 2003;88:2893–2992.CrossRefGoogle Scholar
  94. 94.
    Jennings AM, Millner PC, Ward JD. Hand abnormalities are associated with the complications of diabetes. Diabet Med. 1989;6:43–47.CrossRefPubMedGoogle Scholar
  95. 95.
    Huntley AC. The cutaneous manifestations of diabetes mellitus. J Am Acad Dermatol. 1989;7:427–455.CrossRefGoogle Scholar
  96. 96.
    Kono T, Hayami M, Kobayashi H, Ishii M, Taniguchi S. Acarbose induced generalized erythema multiforme. Lancet. 1999;354:396–397.CrossRefPubMedGoogle Scholar
  97. 97.
    Blumer IR. Severe injection site reaction to insulin detimir. Diabetes Care. 2006;29:946.CrossRefPubMedGoogle Scholar
  98. 98.
    Yang X, Hsu-Hage B, Zhang H, Zhang C, Zhang Y. Women with impaired glucose tolerance during pregnancy have significantly poor pregnancy outcomes. Diabetes Care. 2002;25:1619–1624.CrossRefPubMedGoogle Scholar
  99. 99.
    American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2002;25(1):213–229.CrossRefGoogle Scholar

Supplementary Readings

  1. Ahren B, Gomis R, Standl E. Twelve and fifty two week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2874.CrossRefPubMedGoogle Scholar
  2. American Diabetes Association. Diabetic retinopathy. Diabetes Care. 2002;26(suppl 1):S99–S102.Google Scholar
  3. American Diabetes Association. Diabetic nephropathy. Diabetes Care. 2003;26(suppl 1):S94–S98.Google Scholar
  4. Aschner P, Kipnes MS, Lunjceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29:2632–2638.CrossRefPubMedGoogle Scholar
  5. Bakris GL, Williams M, Dworkin L. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Gorup. Am J Kidney Dis. 2000;41(suppl 1):S22–S25.Google Scholar
  6. Becker RH, Sha S, Frick AD, Fountaine RJ. The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin. Diabetes Care. 2006;29:277–282.CrossRefPubMedGoogle Scholar
  7. Codario R. A guide to combination therapy in type 2 diabetes. Patient Care. 2003;5:16–24.Google Scholar
  8. Codario R. Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome: The Primary Care Guide to Diagnosis and Management. Totowa: Humana; 2005, p. 14.CrossRefGoogle Scholar
  9. Codario R. Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome. The Primary Guide to Diagnosis and Management. Totowa: Humana; 2005, p. 101.CrossRefGoogle Scholar
  10. Codario R. Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome: The Primary Care Guide. Totowa: Humana; 2005, p. 17.CrossRefGoogle Scholar
  11. Dailey GE. Improving oral pharmacologic treatment and management of type 2 diabetes. Manag Care. 2004;13:41–47.PubMedGoogle Scholar
  12. Davidson JA. Rationale for more aggressive guidelines for diabetes control. Endocr Pract. 2002;8(suppl 1):13–14.CrossRefGoogle Scholar
  13. Davis MD, Fisher MR, Gangnon RE. Risk factors for high risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Report#18. Invest Ophthalmol Vis Sci. 1998;39:233–252.PubMedGoogle Scholar
  14. DeFronzo RA. Pathogenesis of type 2 diabetes: metabolic and molecular implications for indentifying diabetes genes. Diabetes Rev. 1997;5:177–269.Google Scholar
  15. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;133:73–74.CrossRefGoogle Scholar
  16. DeFronzo RA, Bergenstahl RM, Cefalu WT. Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise. Diabetes Care. 2005;28:1922–1928.CrossRefPubMedGoogle Scholar
  17. Dressler A, Yki-Jarvinen H, Ziemen M. Less hypoglycemia and better post dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care. 2000;23:1130–1136.CrossRefPubMedGoogle Scholar
  18. Dungan KM, Buse JB. Glucagon-like peptide 1 based therapies for type 2 diabetes. Clin Diabetes. 2005;23:56.CrossRefGoogle Scholar
  19. Egan J, Rubin C, Mathisen A. Pioglitazone 027 Study Group: combination therapy with pioglitazone and metformin in patients with type 2 diabtetes. Diabetes. 1999;48:A117.CrossRefGoogle Scholar
  20. Genuth S, Alberti KG, Bennett P. Follow up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26:3160–3167.CrossRefPubMedGoogle Scholar
  21. Grundy SM. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation. 2002;105:2696–2698.CrossRefPubMedGoogle Scholar
  22. Gominak S, Parry GJ. Diabetic neuropathy. Diabetic neuropathies, classification, clinical feautres and Pathological Basis. Adv Neurol. 2002;99:99–109.Google Scholar
  23. Gulland J. Growing evidence supports role of chromium in prevention treatment of diabetes. Hollistic Primary Care. 2003;4:8.Google Scholar
  24. Henry RR. Glucose control and insulin resistance in non-insulin dependent diabetes mellitus. Ann Intern Med. 1996;124:97–103.CrossRefPubMedGoogle Scholar
  25. Hoogwerf B. Exenatide and pramlintide: new glucose lowering agents for trating diabetes mellitus. Cleve Clin J Med. 2006;73(6):477–484.CrossRefPubMedGoogle Scholar
  26. Izucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002;287:360–372.CrossRefGoogle Scholar
  27. LeRoith D. Beta cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities. Am J Med. 2002;113(suppl 6A):3S–11S.CrossRefPubMedGoogle Scholar
  28. McMahon G, Arky R. Inhaled insulin for diabetes mellitus. N Engl J Med. 2007;356:497–502.CrossRefPubMedGoogle Scholar
  29. Mogensen CE, Vestbo E, Poulsen PL. Micoralbuminuria and potential confounders. A review and some oservations on variability of urinary albumin excretion. Diabetes Care. 1995;18:572–581.PubMedGoogle Scholar
  30. Moses R, Slobodniuk R, Boyages S. Effect of replaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 1999;22:119–124.CrossRefPubMedGoogle Scholar
  31. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone. Diabetes Obes Metab. 2007;9:194–205.CrossRefPubMedGoogle Scholar
  32. Nielsen LL, Baron AD. Pharmacology of exenatide for the treatment of type 2 diabetes. Curr Opin Investig Drugs. 2003;4:401–405.PubMedGoogle Scholar
  33. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide: a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept. 2004;117:77–88.CrossRefPubMedGoogle Scholar
  34. Palumbo PJ. Glycemic control,mealtime glucose excursions and diabetic complications in type 2 diabetes mellitus. Mayo Clin Proc. 2001;76:609–618.PubMedGoogle Scholar
  35. Parkes D, Jodka C, Smith P. Pharmacokinetic actions of exendin-4 in the rat: comparison with glucagon-like peptide-1. Drug Dev Res. 2001;53:260.CrossRefGoogle Scholar
  36. Patton JS, Bukar J, Nagarian S. Inhaled insulin. Adv Drug Deliv Rev. 1999;35:235–247.CrossRefPubMedGoogle Scholar
  37. Pierce NS. Diabetes and exercise. Br J Sports Med. 1999;33:161–173.CrossRefGoogle Scholar
  38. Ramlo-Halsted BA, Edelman SV. The natural history of type 2 diabetes. Implications for clinical practice. Prim Care. 1999;26:771–789.CrossRefPubMedGoogle Scholar
  39. Raskin P, McGill J, Hale P. Replaglinide/rosiglitazone combination therapy of type 2 diabetes. American Diabetes Association 61st Scientific Session. Diabetes. 2001;50(suppl 2):Abstract 516-P.Google Scholar
  40. Ryan EA, Lakey JR, Paty BW, Imes S, Korbutt GS, Kneteman NM. Successful islet transplantation: continued insulin reserve provides long term glycemic control. Diabetes. 2002;51:2148–2157.CrossRefPubMedGoogle Scholar
  41. Salehi M, D’Alessio D. New therapies for type 2 diabetes based on glucagon-like peptide 1. Cleve Clin J Med. 2006;72(4):382–388.CrossRefGoogle Scholar
  42. Salehi M, D’Alessio D. New therapies for type 2 diabetes based on glucagon like peptide-1. Cleve Clin J Med. 2006;73(4):382–388.CrossRefPubMedGoogle Scholar
  43. Schmitz O, Rungby B. Amylin agaonists: a novel approach in the treatment of diabetes. Diabetes. 2004;53(suppl 3):S233.CrossRefPubMedGoogle Scholar
  44. Scott R, Herman G, Zhao P. Twelve week efficacy and tolerability of MK-0431, a dipeptidyl peptidase IV inhibitor, in the treatment of type 2 diabetes. Abstract Book. Diabetes Association 65th Scientific Sessions 2005; 41-O.Google Scholar
  45. Simmons Z, Feldman EL. Update on diabetic neuropathy. Curr Opin Neurol. 2002;15:595–603.CrossRefPubMedGoogle Scholar
  46. Sinnreich M, Taylor BV, Dyck JB. Diabetic neuropathies, classification, clinical features and pathological basis. Neurologist. 2005;11:63–79.Google Scholar
  47. The National Kidney Foundation Kidney Disease Outcome Quality Initiative. Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(suppl 1):S1–S266.Google Scholar
  48. Verne GN, Sninsky CA. Diabetes and the gastrointestinal tract. Gastroenterol Clin North Am. 1998;27:861–874.CrossRefPubMedGoogle Scholar
  49. Yki-Jarvinen H, Ryysy L, Nikkila K. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: a randomized controlled study. Ann Int Med. 1999;130:389–396.CrossRefPubMedGoogle Scholar
  50. Yeh GY, Eisenberg DM, Kaptchuk TJ, Philips RS. Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care. 2003;26:1277–1294.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Ronald A. Codario
    • 1
  1. 1.University of Pennsylvania Health System Thomas Jefferson University HospitalPhiladelphiaUSA

Personalised recommendations